| |
|
|
|
|
|
Beta Blockers
|
Company:
Date:
April 21, 2009
|
|
|
|
|
|
|
|
|
|
BETIMOL® (pronounced bay-ta-mol) is a prescription eye drop medicine used to reduce pressure inside the eye in patients with ocular hypertension or open-angle glaucoma.
It is important that BETIMOL® be used exactly as your doctor tells you. Your doctor will determine how much BETIMOL® you should use and how many times per day. Be sure to follow these instructions carefully. The usual starting dose is one drop of BETIMOL® in the affected eye(s) twice a day. If your eye pressure decreases to a level acceptable by your doctor, he or she may change your dosage schedule to one drop once daily in th
|
Company:
Date:
April 21, 2009
|
|
|
|
|
|
|
|
|
|
COSOPT (dorzolamide hydrochloride-timolol maleate ophthalmic solution) is the combination of a
topical carbonic anhydrase inhibitor and a topical beta-adrenergic receptor blocking agent.
Dorzolamide hydrochloride is described chemically as: (4S-trans)-4-(ethylamino)-5,6-dihydro-6-
methyl-4H-thieno2,3-bthiopyran-2-sulfonamide 7,7-dioxide monohydrochloride.
|
Company:
Date:
April 21, 2009
|
|
|
|
|
|
|
|
|
|
Istalol® is our once-daily, topical ophthalmic solution of timolol, a beta-blocking agent for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Glaucoma is a chronic disease that gradually reduces eyesight without warning and often without symptoms. If undetected and untreated, glaucoma can lead to irreversible eye damage and eventual blindness. According to the Glaucoma Research Foundation, in the United States glaucoma is the cause of an estimated 9-12 of all blindness cases and is the second leading cause of blindness. Currently, it
|
Company:
Date:
April 21, 2009
|
|
|
|
|
|
|
|
|
|
OptiPranolol® is a time-tested option for your patients with open-angle glaucoma or ocular hypertension.In clinical studies, OptiPranolol exhibited comparable efficacy to timolol maleate 0.5 ophthalmic solution.1-3 OptiPranolol may also result in less impairment of exercise-induced tachycardia and has less potential for systemic beta blockade.3
|
Company:
Date:
April 21, 2009
|
|
|
|
|
|
|
|
|
|
Beta Blockers
|
Company:
Date:
April 21, 2009
|
|
|
|
|